Literature DB >> 16829531

Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene.

Morgan Sammons1, Shan Shan Wan, Nancy L Vogel, Edwin J Mientjes, Gerard Grosveld, Brian P Ashburner.   

Abstract

NF-kappaB-mediated transcriptional activation is controlled at several levels including interaction with coregulatory proteins. To identify new proteins capable of modulating NF-kappaB-mediated activation, a cytoplasmic two-hybrid screen was performed using the p65 C-terminal transactivation domain as bait and identified the product of the DEK proto-oncogene. DEK is a ubiquitous nuclear protein that has been implicated in several types of cancer and autoimmune diseases. DEK appears to function in several nuclear processes including transcriptional repression and modulation of chromatin structure. Our data indicate that DEK functions as a transcriptional corepressor to repress NF-kappaB activity. DEK expression blocked p65-mediated activation of an NF-kappaB-dependent reporter gene and also inhibited TNFalpha-induced activation of the reporter gene. Chromatin Immunoprecipitation (ChIP) assays showed that DEK associates with the promoters of the NF-kappaB-regulated cIAP2 and IL-8 genes in untreated cells and dissociates from these promoters upon NF-kappaB binding in response to TNFalpha treatment. Moreover, the expression levels of an NF-kappaB-dependent reporter gene as well as the NF-kappaB-regulated Mcp-1 and IkappaBalpha genes is increased in DEK-/- cells compared with wild-type cells. ChIP assays on these promoters show enhanced and prolonged binding of p65 and increased recruitment of the P/CAF coactivator. Overall, these data provide further evidence that DEK functions to negatively regulate transcription.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829531     DOI: 10.1074/jbc.M600915200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

3.  Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Authors:  Maroun Karam; Morgan Thenoz; Valérie Capraro; Jean-Philippe Robin; Christiane Pinatel; Agnès Lancon; Perrine Galia; David Sibon; Xavier Thomas; Sophie Ducastelle-Lepretre; Franck Nicolini; Mohamed El-Hamri; Youcef Chelghoun; Eric Wattel; Franck Mortreux
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 4.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

6.  DEK over-expression promotes mitotic defects and micronucleus formation.

Authors:  Marie C Matrka; Robert F Hennigan; Ferdinand Kappes; Monica L DeLay; Paul F Lambert; Bruce J Aronow; Susanne I Wells
Journal:  Cell Cycle       Date:  2015-05-06       Impact factor: 4.534

Review 7.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

8.  Mixed lineage kinase 3 negatively regulates IKK activity and enhances etoposide-induced cell death.

Authors:  Eric T Cole; Yu Zhan; Widian F Abi Saab; Amanda C Korchnak; Brian P Ashburner; Deborah N Chadee
Journal:  Biochim Biophys Acta       Date:  2009-09-25

Review 9.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

10.  DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.

Authors:  F Kappes; J Fahrer; M S Khodadoust; A Tabbert; C Strasser; N Mor-Vaknin; M Moreno-Villanueva; A Bürkle; D M Markovitz; E Ferrando-May
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.